Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Viatris vs. AbbVie

TheMotleyFool

0 0

With a market cap of nearly $16 billion, the generic drugmaker Viatris (NASDAQ: VTRS) is minuscule in comparison to the profitable pharma titan AbbVie's (NYSE: ABBV) $228 billion. But, with Viatris' revenue growth starting to take off just as AbbVie's is decelerating, the fact that the smaller company is currently unprofitable may not deter investors.

And, since each company is in the midst of transitionary periods that are unprecedented, the risks of investing in either are higher than they'd normally be. Let's consider the merits of these stocks to weigh the chances of success moving forward.

Image source: Getty Images.

Source Fool.com

Like: 0

VTRS

Share